康希诺 (688185)
CanSino Biologics Inc.
K-Line Chart
No K-line data available
Company NameCanSino Biologics Inc.
Listing Date2020-08-13
Issue Price209.71RMB
Registered Capital24744.989910k RMB
Legal RepresentativeXUEFENG YU
Registered Address401-420, 4th Floor, West District Biomedical Park, No. 185 Nan Da Jie, West District, Tianjin Economic-Technological Development Area
IndustryBiological Products
Main BusinessThe company is an innovative vaccine enterprise dedicated to the research, development, production, and sales of vaccines that meet Chinese and international standards. Under the leadership of management, the company has advanced the R&D of a series of innovative vaccines. Its R&D pipeline covers vaccines for several diseases with significant clinical demand, including meningitis, Ebola virus disease, diphtheria, pertussis, tetanus (DPT), pneumonia, tuberculosis, COVID-19, and herpes zoster.
Company ProfileCanSino Biologics Inc. (Abbreviation: CanSino Biologics, Stock Code: 6185.HK) was registered in 2009 in the Tianjin Binhai New Area. It is a national high-tech enterprise founded by a returning team of senior executives from multinational pharmaceutical companies. CanSino Biologics is committed to providing global solutions for the prevention of infectious diseases. It specializes in the research, development, production, and commercialization of high-quality human vaccines and is a leading high-tech biologics enterprise in China. In March 2019, CanSino Biologics was listed on the Main Board of the Hong Kong Stock Exchange as an H-share company. In January 2020, the company formally submitted an application for listing on the STAR Market, which was accepted. The intended use of the raised funds is for expanding production capacity for new vaccines and R&D of new vaccine products.
CanSino Biologics' R&D team brings together renowned scientists and seasoned vaccine industry experts who previously led innovative international vaccine R&D at global pharmaceutical giants such as Sanofi Pasteur, AstraZeneca, and Wyeth (now Pfizer). The company has established four core technology platforms based on adenovirus vector vaccine technology, protein structure design and recombinant technology, conjugation technology, and formulation technology. It possesses multiple core vaccine intellectual property rights and proprietary technologies.
Stock Details
1. Key Indicators
- Total Shares(W): 734059.07
- Circulating A-Shares(W): 734059.07
- Earnings Per Share(RMB): 1.23
- Net Assets Per Share(RMB): 5.67
- Operating Revenue(W RMB): 1345261.60
- Total Profit(W RMB): 1345261.60
- **Net Profit Attributable to Parent(W RMB) **: 1345261.60
- Net Profit Growth Rate(%): -55.89
- Weighted Return on Equity(%): 4.6500
- Operating Cash Flow Per Share(RMB): 1.23
- Undistributed Profit Per Share(RMB): 1.23
- Capital Reserve Per Share(RMB): 1.23
2. Main Business
The main business covers:
- New energy vehicle manufacturing and sales
- Intelligent transportation system R&D
- Fuel cell technology development
- Autonomous driving solutions
3. Company Basic Information
- Company Name: Dongfeng Automobile Co., Ltd.
- Listing Date: 2001-05-18
- Industry: Automobile Manufacturing
- Address: Economic and Technological Development Zone, Wuhan City, Hubei Province
- Website: https://www.dongfeng.com.cn/
- Company Profile: The company was established with Beijing Capital Venture Group as the main sponsor. It is a listed company focusing on automobile manufacturing and intelligent transportation fields.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | China Securities Finance Co., Ltd. | National Team | 5,000 | 10.2 |
| 2 | China Asset Management Co., Ltd. | Public Fund | 3,200 | 6.5 |
| 3 | Hillhouse Capital Management | Private Equity Fund | 2,800 | 5.7 |
| 4 | National Social Security Fund | National Team | 2,500 | 5.1 |
| 5 | E Fund Management Co., Ltd. | Public Fund | 2,000 | 4.1 |
| 6 | China Universal Asset Management Co., Ltd. | Public Fund | 1,800 | 3.7 |
| 7 | CITIC Securities Co., Ltd. | Broker | 1,500 | 3.1 |
| 8 | Guotai Junan Securities Co., Ltd. | Broker | 1,200 | 2.4 |
| 9 | China Merchants Bank Co., Ltd. | Bank | 1,000 | 2.0 |
| 10 | ICBC Credit Suisse Asset Management Co., Ltd. | Public Fund | 900 | 1.8 |
5. Concept Sectors
- Carbon Neutrality
- Intelligent Transportation
- Fuel Cell
- Autonomous Driving
- New Energy Vehicle
- Hydrogen Energy
- Huawei Auto
- Internet of Vehicles (IoV)
Remarks
- Data update date: 2025-11-02
- Data source: Public Market Information